Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Imlunestrant improves PFS in breast cancer, phase III data show

Eli Lilly and Co. announced results from the phase III EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, in patients with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Phase III trial shows improved PFS in treatment of CLL using pirtobrutinib

Eli Lilly and Co. announced results from the phase III BRUIN CLL-321 trial evaluating pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Calquence + Venetoclax shows superior PFS in untreated CLL in AMPLIFY phase III trial

Positive results from the AMPLIFY phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Tecvayli demonstrates potential in MM

Johnson & Johnson announced new frontline data featuring Tecvayli (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance settings.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Carvykti demonstrates higher rates of MRD negativity, phase III study shows

Johnson & Johnson announced new results from the phase III CARTITUDE-4 study that show a single infusion of Carvykti (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease negativity rates (10-5) in patients with relapsed or refractory multiple myeloma who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor, compared to standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.

December 13, 2024

Vol.50 No.46

Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

YOU MAY BE INTERESTED IN

Lynparza demonstrates survival benefit in early breast cancer, phase III trial data show

Imlunestrant improves PFS in breast cancer, phase III data show

Phase III trial shows improved PFS in treatment of CLL using pirtobrutinib

Calquence + Venetoclax shows superior PFS in untreated CLL in AMPLIFY phase III trial

Tecvayli demonstrates potential in MM

Carvykti demonstrates higher rates of MRD negativity, phase III study shows

Renew today!

Subscriber content

Never miss an issue!

Login